British drugmaker AstraZeneca is working with regulators to investigate a lower dosage of its vaccine that performed better than a full dosage, a spokesman for the company said on Thursday, after its chief executive was quoted as saying an additional global trial was likely. This report produced by Jillian Kitchener.
AstraZeneca and the University of Oxford are facing criticism over their COVID-19 vaccine trial results. According to Business Insider the criticism comes after AstraZeneca admitted to a mistake in the vaccine dosage. During the vaccine trial, some patients got two full doses of the vaccine. Others had a half-dose in their first shot, followed by a full dose. On Wednesday, an AstraZeneca executive described the "mistake" as "serendipity.
A manufacturing error is raising concerns about a promising COVID-19 vaccine being developed. The vaccine was developed by pharmaceutical company AstraZeneca and the University of Oxford. Less than a week after we learned about it, the developers have admitted to a manufacturing error. The error resulted from two different doses during the recently concluded phase III trial. AstraZeneca and the University of Oxford described the vaccine as being 70% effective.
Brazil's health regulator has suspended a clinical trial for China's Sinovac coronavirus vaccine citing a severe adverse event, surprising the trial organizers who countered there had been a death but..